Purchase this article with an account.
S. Ben Yahia, H. Zeghidi, S. Attia, S. Zaouali, A. Ladjimi, M. Khairallah; Effects of intravitreal triamcinolone acetonide on diabetic retinal neovascularization . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4142.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose:To evaluate the effects of intravitreal triamcinolone acetonide (TA) on diabetic retinal neovascularization. Methods:The study included 11 eyes of 10 patients with diabetic macular edema and associated retinal and/or optic disc neovascularization persisting after scatter laser photocoagulation. All patients received an intravitreal injection of 4 mg of TA. No additional laser photocoagulation was performed after TA injection. Evaluation before injection and throughout follow–up included measurement of best–corrected visual acuity, slit–lamp examination, fundus photography, and fluorescein angiography. Follow–up period ranged from 3 to 12 months (mean 6.4 months). Results:Mean visual acuity improved from 20/300 to 20/160 (p = 0.039). Macular edema diminished or resolved completely in all eyes. Neovascularization substantially regressed in 10 eyes (90.9%) and remained unchanged in one eye (9.1%). None of the eyes developed vitreous hemorrhage after treatment. An intraocular pressure elevation occurred in 3 eyes (27.3%), and was successfully treated by topical medication. No other complications, such as endophthalmitis or pseudo–endophthalmitis were recorded. Conclusions:Intravitreal injection of TA may be useful for the treatment of residual diabetic retinal neovascularization. Further studies are warranted to assess the long–term efficacy and safety, and the need for retreatment.
This PDF is available to Subscribers Only